Here are four things to know.
1. QuintilesIMS analysts expects U.S. drug spending to jump 4 percent to 7 percent through 21, hitting $580 billion to $610 billion.
2. While analysts originally predicted an average spending growth of 6 percent to 9 percent, the company lowered its forecast due to fewer new drug approvals, increasing market competition and heightened scrutiny over prices.
3. When manufacturer discounts and rebates are considered, analysts expect spending to jump 2 percent to 5 percent through 2021, reaching $375 billion to $405 billion.
4. In 2016, prescription drug spending increased 5.8 percent from the year prior to $450 billion based on list prices. When adjusted for discounts and rebates, spending jumped 4.8 percent to $323 billion.
To view the full report, click here.
More articles on supply chain:
4 experts’ tips on modernizing hospital supply chains for the digital age
AstraZeneca wins FDA approval for immunotherapy drug
Physicians prescribe fewer branded drugs when hospitals limit drug rep interactions
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
